Seek Returns

DHR vs. IQV: Danaher vs. IQVIA Stock Comparison

How do Danaher (DHR) and IQVIA (IQV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and IQVIA (IQV) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Danaher (DHR) and IQVIA (IQV)
Profile ItemDHRIQV
NameDanaher Corp.IQVIA Holdings Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization161.86 billion USD44.80 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateDecember 29, 1978May 9, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

DHR
IQV
GSPC
Loading price history…
Danaher (DHR) vs. IQVIA (IQV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Danaher (DHR) and IQVIA (IQV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Danaher (DHR) and IQVIA (IQV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Total Return (1Y)11.88%32.11%
Total Return (3Y, Annualized)6.67%13.15%
Total Return (5Y, Annualized)-2.05%2.00%

Risk Profile

Drawdown History

DHR
IQV
GSPC
Loading price history…
Danaher (DHR) vs. IQVIA (IQV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Danaher (DHR) and IQVIA (IQV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Volatility (1Y, Annualized)30.61%40.77%
Beta (5Y)0.761.14
Max Drawdown (5Y)-43.31%-51.52%
Avg. Volume (3M)3.94M1.40M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
DHR and IQV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Sharpe Ratio (1Y)0.250.68
Sortino Ratio (1Y)0.351.03

Profitability

ROE (TTM)

Both Danaher (DHR) at 8.19% and IQVIA (IQV) at 21.39% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max
109.18%
DHR
8.19%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max
109.18%
IQV
21.39%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Danaher (DHR) at 16.91% and IQVIA (IQV) at 8.05% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max
18.05%
DHR
16.91%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max
18.05%
IQV
8.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Danaher (DHR) at 21.13% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max
83.12%
DHR
21.13%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max
83.12%
Q3
14.77%
IQV
13.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
ROE (TTM)8.19%21.39%
ROA (TTM)4.06%5.08%
Net Margin (TTM)16.91%8.05%
Operating Margin (TTM)21.13%13.73%
Gross Margin (TTM)59.36%33.07%

Growth

Revenue Growth

Both Danaher (DHR) at 2.90% and IQVIA (IQV) at 5.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Danaher (DHR) at -4.54% and IQVIA (IQV) at 4.67% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Revenue Growth (YoY)2.90%5.87%
Revenue Growth (3Y CAGR)-2.67%4.21%
EPS Growth (YoY)-4.54%4.67%
EPS Growth (3Y CAGR)-19.44%11.08%

Financial Strength

Current Ratio (MRQ)

Both Danaher (DHR) at 1.63 and IQVIA (IQV) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
DHR
1.63
Min
0.10

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
IQV
0.83
Min
0.10
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Danaher (DHR) at 0.52 is near its industry mid-range for debt-to-equity ratio, while IQVIA (IQV) at 2.40 sits above its benchmark range, pointing to a heavier debt load relative to equity.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max
1.42
Q3
0.65
DHR
0.52
Median
0.15
Q1
0.02
Min
0.00

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV
2.40
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Current Ratio (MRQ)1.630.83
Debt / Equity (MRQ)0.522.40
Net Debt / EBITDA2.684.46

Dividends

Dividend Yield (TTM)

IQVIA (IQV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR
0.67%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

IQVIA (IQV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR
25.17%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
Dividend Yield (TTM)0.67%0.00%
Dividend Payout Ratio (TTM)25.17%0.00%

Valuation

P/E Ratio (TTM)

Both Danaher (DHR) at 38.12 and IQVIA (IQV) at 33.07 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max
85.34
Q3
43.46
DHR
38.12
Median
26.69
Q1
13.30
Min
0.07

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max
85.34
Q3
43.46
IQV
33.07
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Danaher (DHR) at 6.32 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max
58.18
Q3
25.77
Median
7.30
DHR
6.32
Q1
3.01
Min
0.01

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
IQV
2.59
Min
0.01
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Danaher (DHR) at 3.02 is valued about in line with its industry on P/B ratio, while IQVIA (IQV) at 6.73 carries an above-peer premium to book — IQV is pricier on assets.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max
13.53
Q3
6.54
Median
3.25
DHR
3.02
Q1
1.69
Min
-5.59

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max
13.53
IQV
6.73
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Danaher (DHR) vs. IQVIA (IQV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and IQVIA (IQV)
MetricDHRIQV
P/E Ratio (TTM)38.1233.07
P/S Ratio (TTM)6.322.59
P/B Ratio (MRQ)3.026.73
Free Cash Flow Yield (TTM)2.93%4.72%